CN107530340B - 治疗脑肿瘤的方法 - Google Patents

治疗脑肿瘤的方法 Download PDF

Info

Publication number
CN107530340B
CN107530340B CN201680020652.9A CN201680020652A CN107530340B CN 107530340 B CN107530340 B CN 107530340B CN 201680020652 A CN201680020652 A CN 201680020652A CN 107530340 B CN107530340 B CN 107530340B
Authority
CN
China
Prior art keywords
plinabulin
mice
brain tumor
agents
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680020652.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN107530340A (zh
Inventor
黄岚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DALIAN WANCHUN BIOTECHNOLOGY Co Ltd
Original Assignee
Dalian Wanchun Brin Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56880412&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN107530340(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dalian Wanchun Brin Pharmaceutical Co ltd filed Critical Dalian Wanchun Brin Pharmaceutical Co ltd
Publication of CN107530340A publication Critical patent/CN107530340A/zh
Application granted granted Critical
Publication of CN107530340B publication Critical patent/CN107530340B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Radiation-Therapy Devices (AREA)
CN201680020652.9A 2015-03-06 2016-03-02 治疗脑肿瘤的方法 Active CN107530340B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562129623P 2015-03-06 2015-03-06
US62/129,623 2015-03-06
US201562249807P 2015-11-02 2015-11-02
US62/249,807 2015-11-02
PCT/US2016/020396 WO2016144636A1 (en) 2015-03-06 2016-03-02 Method of treating a brain tumor

Publications (2)

Publication Number Publication Date
CN107530340A CN107530340A (zh) 2018-01-02
CN107530340B true CN107530340B (zh) 2021-06-08

Family

ID=56880412

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680020652.9A Active CN107530340B (zh) 2015-03-06 2016-03-02 治疗脑肿瘤的方法

Country Status (16)

Country Link
US (2) US10076518B2 (enExample)
EP (1) EP3265091A4 (enExample)
JP (2) JP6904570B2 (enExample)
KR (1) KR102623404B1 (enExample)
CN (1) CN107530340B (enExample)
AU (2) AU2016229295B2 (enExample)
BR (1) BR112017018964A2 (enExample)
CL (1) CL2017002242A1 (enExample)
HK (1) HK1249051A1 (enExample)
IL (1) IL254262A0 (enExample)
MX (1) MX385914B (enExample)
MY (1) MY194341A (enExample)
RU (1) RU2728796C2 (enExample)
SG (1) SG11201707128TA (enExample)
WO (1) WO2016144636A1 (enExample)
ZA (1) ZA201706035B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102623404B1 (ko) 2015-03-06 2024-01-11 비욘드스프링 파마수티컬스, 인코포레이티드. 뇌 종양 치료 방법
JP6769982B2 (ja) 2015-03-06 2020-10-14 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド Ｒａｓ変異と関連するがんの治療方法
ES2910035T3 (es) 2015-07-13 2022-05-11 Beyondspring Pharmaceuticals Inc Composiciones de plinabulina
CA3013467A1 (en) 2016-02-08 2017-08-17 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
EP3463337A4 (en) 2016-06-06 2020-02-12 Beyondspring Pharmaceuticals, Inc. COMPOSITION AND METHOD FOR REDUCING NEUTROPENIA
CN110431135A (zh) 2017-01-06 2019-11-08 大连万春布林医药有限公司 微管蛋白结合化合物及其治疗用途
KR20190109479A (ko) * 2017-02-01 2019-09-25 비욘드스프링 파마수티컬스, 인코포레이티드. 호중구감소증의 감소 방법
SG11202006985TA (en) 2018-01-24 2020-08-28 Beyondspring Pharmaceuticals Inc Composition and method for reducing thrombocytopenia via the administration of plinabulin
WO2020018700A1 (en) * 2018-07-18 2020-01-23 Manzanita Pharmaceuticals, Inc. Conjugates for delivering an anti-cancer agent to nerve cells, methods of use and methods of making thereof
ES3017257T3 (en) * 2020-01-22 2025-05-12 Stichting Het Nederlands Kanker Inst Antoni Van Leeuwenhoek Ziekenhuis Abt-751 and ionizing radiation for use in treating a brain tumor
BR112022020595A2 (pt) * 2020-04-10 2023-01-17 Lantern Pharma Inc Métodos hidroxiureametil-acilfulveno para tratamento de câncer do cérebro ou câncer do snc.
CA3204446A1 (en) * 2021-01-08 2022-07-14 Aditya Kulkarni Treatment of brain metastases and cns metastases using illudins or hydroxylureamethyl acylfulvene
WO2022216908A1 (en) * 2021-04-09 2022-10-13 Beyondspring Pharmaceuticals, Inc. Therapeutic compositions and methods for treating tumors
CN117860672A (zh) * 2022-10-11 2024-04-12 大连万春布林医药有限公司 一种普那布林胶束组合物及其制备方法
CN120682197A (zh) * 2024-03-19 2025-09-23 大连万春布林医药有限公司 普那布林的盐晶型

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS509164A (enExample) 1973-05-11 1975-01-30
AU576322B2 (en) 1983-07-22 1988-08-25 Ici Australia Limited Alpha-substituted-alpha-cyanomethyl alcohols
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
JPS6411523A (en) 1987-07-06 1989-01-17 Kawashima Tekko Kk Dish feeder in tableware washing machine
JPH059164A (ja) 1991-07-02 1993-01-19 Sumitomo Chem Co Ltd 光学活性マンデロニトリル誘導体の製造方法
GB9217331D0 (en) 1992-08-14 1992-09-30 Xenova Ltd Pharmaceutical compounds
EP0674510B1 (en) 1992-11-27 1998-08-05 Napro Biotherapeutics, Inc. Injectable composition comprising paclitaxel
JPH0725858A (ja) 1993-07-13 1995-01-27 Otsuka Pharmaceut Co Ltd ピペラジン誘導体
GB9402807D0 (en) 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
GB9402809D0 (en) 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
GB9426224D0 (en) 1994-12-23 1995-02-22 Xenova Ltd Pharmaceutical compounds
US5891877A (en) 1995-02-14 1999-04-06 Xenova Limited Pharmaceutical compounds
US5874443A (en) 1995-10-19 1999-02-23 Trega Biosciences, Inc. Isoquinoline derivatives and isoquinoline combinatorial libraries
US5886210A (en) 1996-08-22 1999-03-23 Rohm And Haas Company Method for preparing aromatic compounds
JP3131574B2 (ja) 1996-09-04 2001-02-05 新日本製鐵株式会社 新規抗腫瘍物質、該物質を製造するための微生物及び方法、並びに該物質を有効成分とする細胞周期阻害剤及び抗腫瘍剤
US5939098A (en) * 1996-09-19 1999-08-17 Schering Corporation Cancer treatment with temozolomide
US5922683A (en) 1997-05-29 1999-07-13 Abbott Laboratories Multicyclic erythromycin derivatives
EP2201945B1 (en) 1997-11-21 2013-03-06 Purdue Neuroscience Company Use of substituted 2-aminoacetamides for treating or ameliorating anxiety
CN1173946C (zh) 1998-01-29 2004-11-03 阿温蒂斯药物公司 制备n-[(脂族或芳族)羰基]-2-氨基乙酰胺化合物和环化化合物的方法
US7141603B2 (en) 1999-02-19 2006-11-28 The Regents Of The University California Antitumor agents
US6069146A (en) 1998-03-25 2000-05-30 The Regents Of The University Of California Halimide, a cytotoxic marine natural product, and derivatives thereof
US6333323B1 (en) 1998-03-26 2001-12-25 Shionogi & Co., Ltd. Indole derivatives with antiviral activity
US6509331B1 (en) 1998-06-22 2003-01-21 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
FR2784988B1 (fr) 1998-10-23 2002-09-20 Adir Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6358957B1 (en) 1998-11-12 2002-03-19 Nereus Pharmaceuticals, Inc. Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds
US7026322B2 (en) 1998-11-12 2006-04-11 Nereus Pharmaceuticals, Inc. Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds
DK1210428T3 (en) 1999-08-23 2015-06-15 Dana Farber Cancer Inst Inc PD-1, a receptor for B7-4 AND USE THEREOF
IL148021A0 (en) 1999-08-23 2002-09-12 Dana Farber Cancer Inst Inc Novel b7-4 molecules and uses therefor
PT1234031T (pt) 1999-11-30 2017-06-26 Mayo Foundation B7-h1, uma nova molécula imunoregulatória
BR0017067A (pt) 2000-01-18 2002-10-22 Nereus Pharmaceuticals Inc Inibidor de divisão de célula, desidrogenase, método para a produção de um inibidor de divisão de célula e composto
ATE417614T1 (de) 2000-05-09 2009-01-15 Angiorx Corp Piperazindion-verbindungen
JP2004518731A (ja) 2000-12-28 2004-06-24 ニューロクライン バイオサイエンシーズ， インコーポレイテッド 三環式ｃｒｆレセプターアンタゴニスト
US7012100B1 (en) 2002-06-04 2006-03-14 Avolix Pharmaceuticals, Inc. Cell migration inhibiting compositions and methods and compositions for treating cancer
US7935704B2 (en) 2003-08-01 2011-05-03 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
ES2295695T3 (es) 2002-08-02 2008-04-16 Nereus Pharmaceuticals, Inc. Deshidrofenilahistinas y sus analogos y la sintesis de deshidrofenilahistinas y sus analogos.
US7919497B2 (en) * 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
WO2004056875A1 (en) 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
JP2007520565A (ja) 2004-02-04 2007-07-26 ネレアス ファーマシューティカルズ インコーポレイテッド デヒドロフェニラヒスチン及びそれらの類似体、並びにデヒドロフェニラヒスチン及びそれらの類似体の合成
DE202004018940U1 (de) 2004-12-07 2006-04-13 Asf Verwaltungs Gmbh Druckverschluß, Druckverschlußband und wiederverschließbarer Beutel
EP2418278A3 (en) 2005-05-09 2012-07-04 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
KR101607288B1 (ko) 2005-07-01 2016-04-05 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
EP2335733B1 (en) * 2006-01-18 2014-08-06 Merck Patent GmbH Specific therapy using integrin ligands for treating cancer
US8129527B2 (en) 2006-11-03 2012-03-06 Nereus Pharmacuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
AU2009204194A1 (en) 2008-01-08 2009-07-16 Bristol-Myers Squibb Company Combination of anti-CTLA4 antibody with tubulin modulating agents for the treatment of proliferative diseases
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
TWI729512B (zh) 2008-12-09 2021-06-01 美商建南德克公司 抗pd-l1抗體及其於增進t細胞功能之用途
WO2010114922A1 (en) * 2009-03-31 2010-10-07 Agios Pharmaceuticals, Inc. Methods of treating cancer having an aberrant egfr or kras genotype
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
TWI483938B (zh) 2009-08-10 2015-05-11 Univ Texas 以內皮素受體抑制劑處理星狀腫瘤細胞
CN104961829B (zh) 2009-11-24 2018-08-21 米迪缪尼有限公司 针对b7-h1的靶向结合剂
US20130064831A1 (en) 2010-05-17 2013-03-14 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
EP2576514A1 (en) * 2010-06-04 2013-04-10 Exonhit Sa Substituted isoquinolines and their use as tubulin polymerization inhibitors
JP2012033526A (ja) 2010-07-28 2012-02-16 Fuji Electric Co Ltd 薄膜太陽電池およびその製造方法
WO2012035436A1 (en) 2010-09-15 2012-03-22 Tokyo University Of Pharmacy And Life Sciences Plinabulin prodrug analogs and therapeutic uses thereof
TWI386203B (zh) 2011-01-07 2013-02-21 Univ China Medical 治療腦癌或用以降低腦癌細胞對替莫唑胺之抗藥性之醫藥組合物及其應用
DK2699264T3 (en) 2011-04-20 2018-06-25 Medimmune Llc ANTIBODIES AND OTHER MOLECULES BINDING B7-H1 AND PD-1
AU2013204313C1 (en) * 2012-06-01 2016-04-07 Bionomics Limited Combination Therapy
WO2014160183A1 (en) 2013-03-13 2014-10-02 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Methods for modulating chemotherapeutic cytotoxicity
EP2988668B1 (en) 2013-04-24 2019-07-24 Tel HaShomer Medical Research Infrastructure and Services Ltd. Magnetic resonance maps for analyzing tissue
AU2013402794B2 (en) 2013-10-11 2020-02-27 Beyondspring Inc. Cancer treatment with combination of plinabulin and taxane
US9850225B2 (en) 2014-04-14 2017-12-26 Bristol-Myers Squibb Company Compounds useful as immunomodulators
AU2016219204B2 (en) 2015-02-12 2021-01-21 Beyondspring Pharmaceuticals, Inc. Use of Plinabulin in combination with immune checkpoint inhibitors
JP6769982B2 (ja) 2015-03-06 2020-10-14 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド Ｒａｓ変異と関連するがんの治療方法
KR102623404B1 (ko) 2015-03-06 2024-01-11 비욘드스프링 파마수티컬스, 인코포레이티드. 뇌 종양 치료 방법
ES2910035T3 (es) 2015-07-13 2022-05-11 Beyondspring Pharmaceuticals Inc Composiciones de plinabulina
CA3013467A1 (en) 2016-02-08 2017-08-17 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
EP3463337A4 (en) 2016-06-06 2020-02-12 Beyondspring Pharmaceuticals, Inc. COMPOSITION AND METHOD FOR REDUCING NEUTROPENIA
CN110431135A (zh) 2017-01-06 2019-11-08 大连万春布林医药有限公司 微管蛋白结合化合物及其治疗用途
KR20190109479A (ko) 2017-02-01 2019-09-25 비욘드스프링 파마수티컬스, 인코포레이티드. 호중구감소증의 감소 방법
SG11201908420WA (en) 2017-03-13 2019-10-30 Beyondspring Pharmaceuticals Inc Compositions of plinabulin and use thereof

Also Published As

Publication number Publication date
MX385914B (es) 2025-03-18
HK1249051A1 (zh) 2018-10-26
ZA201706035B (en) 2019-12-18
BR112017018964A2 (pt) 2018-05-22
EP3265091A1 (en) 2018-01-10
AU2016229295A1 (en) 2017-09-28
RU2017131448A3 (enExample) 2019-08-20
US20180042921A1 (en) 2018-02-15
RU2017131448A (ru) 2019-04-08
MX2017011375A (es) 2018-01-23
AU2016229295B2 (en) 2021-11-04
US20190000841A1 (en) 2019-01-03
CN107530340A (zh) 2018-01-02
AU2021254549B2 (en) 2024-10-24
JP6904570B2 (ja) 2021-07-21
SG11201707128TA (en) 2017-09-28
AU2021254549A1 (en) 2021-11-18
CA2978679A1 (en) 2016-09-15
HK1250007A1 (zh) 2018-11-23
KR102623404B1 (ko) 2024-01-11
KR20170123642A (ko) 2017-11-08
US10076518B2 (en) 2018-09-18
US10357491B2 (en) 2019-07-23
JP2021091695A (ja) 2021-06-17
EP3265091A4 (en) 2018-08-01
JP2018507245A (ja) 2018-03-15
CL2017002242A1 (es) 2018-04-02
RU2728796C2 (ru) 2020-07-31
IL254262A0 (en) 2017-10-31
JP7264331B2 (ja) 2023-04-25
WO2016144636A1 (en) 2016-09-15
MY194341A (en) 2022-11-29

Similar Documents

Publication Publication Date Title
CN107530340B (zh) 治疗脑肿瘤的方法
CN107530341B (zh) 治疗与ras突变相关的癌症的方法
US20200179412A1 (en) Compositions for the treatment of fibrosis
BR112020019325A2 (pt) Método de tratamento de doença fibrótica
CA2978679C (en) Method of treating a brain tumor
HK1250007B (zh) 治疗脑肿瘤的方法
NZ749857B2 (en) Method of treating a brain tumor
NZ749857A (en) Method of treating a brain tumor
US20180296564A1 (en) Method for preventing and/or treating chronic traumatic encephalopathy - iii
HK1250008B (zh) 治疗与ras突变相关的癌症的方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1250007

Country of ref document: HK

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20190806

Address after: No. 19-6 ShuangD Port and ShuangD4 Street, Dalian Economic and Technological Development Zone, Liaoning Province

Applicant after: DALIAN WANCHUN BIOTECHNOLOGY CO., LTD.

Address before: American New York

Applicant before: Wan Chun pharmaceutical company

GR01 Patent grant
GR01 Patent grant